Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- David Geffen School of Medicine at Ucla
Los Angeles, California, United States
Gary Schiller, MDRecruiting - University of Florida
Gainesville, Florida, United States
Christopher Cogle R Cogle, MDRecruiting - University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Justin Watts, MDRecruiting - University of Kansas Cancer Center and Medical Pavilion
Westwood, Kansas, United States
Tara Lin, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 31 Oct 2019
- Completion
- 31 Oct 2020
- Last update posted
- 4 Jun 2018
- Registered enrollment
- 105
- Registry id
- NCT02576301
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.